![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
July 16, 2026
This trial is testing an immune-based treatment combination (teclistamab and pomalidomide) for patients with multiple myeloma that has come back early
June 29, 2026
This study is using PET imaging to guide treatment for prostate cancer recurrence
May 28, 2026
ACHIEVE (EA5221) is the first lung cancer clinical trial for older patients with metastatic NSCLC, comparing immunotherapy (pembrolizumab) with and without chemotherapy
May 20, 2026
This phase 3 clinical trial is comparing aromatase inhibitors and ribociclib, with and without chemotherapy, to prevent recurrence
April 24, 2026
This phase 2 trial is evaluating pembrolizumab immunotherapy after surgery in patients with recurrent or second primary head and neck cancer with high-risk features
March 30, 2026
This phase 3 clinical trial is evaluating a less intensive treatment approach for adults aged 75+ with early-stage melanoma
April 24, 2026
This phase 3 trial seeks to determine if there is any survival benefit from adding a fourth drug to induction therapy—and if so, in which patients
February 27, 2026
This phase 2 trial is evaluating whether broccoli sprout extract (sulforaphane) will reduce the risk of melanoma returning
February 27, 2026
This phase 2 study is evaluating ivonescimab, a novel therapy designed to target the PD-1 and VEGF pathways simultaneously
February 27, 2026
Liquid biopsies are now permitted for eligibility determination, while trial participants may use progression biopsies to explore treatment options
January 30, 2026
The new objective is to identify biomarkers associated with malignant risk in pancreatic cysts, requiring current participants to reconsent
January 30, 2026
This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments